Executives of EpiPen maker Mylan NV are unlikely to suffer a reduction in their pay from the company’s recent $465 million settlement of allegations that it improperly overcharged Medicaid for the lifesaving drug.
from the Wall Street Journal
Executives rarely lose out
for acting like some kind of lout.
Their bonus secure,
they're seldom demure;
in fact honest dealing they flout!
No comments:
Post a Comment